Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Avidity Biosciences, Inc. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is characterized by dispersion, as the 4 actions are assigned to distinct examiners across distinct art units. This distribution indicates that each pending matter is being evaluated in a unique technical and administrative environment at the USPTO.
The busiest examiner, HUYNH, PHUONG N, is responsible for 1 busiest examiner pending office action. With distinct examiners each handling 1 case, no individual examiner has a disproportionate influence over the company's pending biotechnology and pharmaceutical matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| LOCKARD, JON MCCLELLAND | 1 | 74.6% | +27.2% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18052897 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | GIBBS, TERRA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19097593 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | LOCKARD, JON MCCLELLAND | 33d |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | BENAVIDES, JENNIFER ANN | 35d |
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | HUYNH, PHUONG N | — |
| 18052897 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | GIBBS, TERRA C | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1647 | 1 |
| 1675 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19329403 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | HUYNH, PHUONG N | 1641 | §112 | Final Rejection | — | Pending | Sep 15, 2025 |
| 19097593 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING | LOCKARD, JON MCCLELLAND | 1647 | §112 | Final Rejection | 33d | Pending | Apr 01, 2025 |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | BENAVIDES, JENNIFER ANN | 1675 | DP | Non-Final OA | 35d | Pending | Apr 16, 2024 |
| 18052897 | COMPOSITIONS AND METHODS OF TREATING POMPE DISEASE | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial